Jury Hits Novartis With $178M Verdict In Drug Patent Fight
By Dorothy Atkins (July 22, 2021, 3:31 PM EDT) -- A California federal jury hit Novartis with a $177.8 million verdict Thursday for selling a skin cancer drug that infringes two patents owned by a Daiichi Sankyo subsidiary, rejecting Novartis' arguments that the patents are invalid and awarding the entire sum the plaintiff sought.
A jury found that Novartis owes Plexxikon Inc. $177.8 million for willfully infringing its patents through the Swiss company's popular skin cancer drug Tafinlar. (iStock) After less than four hours of deliberating, a unanimous eight-member jury panel of six women and two men rejected arguments that the patents are invalid for being too broad and anticipated as...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!